Alan Kaplan1. 1. 17 Bedford Park Ave, Richmond Hill, ON L4C 2N9. for4kids@gmail.com.
Abstract
OBJECTIVE: To provide a clinical summary of the Canadian clinical practice guidelines for chronic rhinosinusitis (CRS) that includes recommendations relevant for family physicians. QUALITY OF EVIDENCE: Guideline authors performed a systematic literature search and drafted recommendations. Recommendations received both strength of evidence and strength of recommendation ratings. Input from external content experts was sought, as was endorsement from Canadian medical societies (Association of Medical Microbiology and Infectious Disease Canada, Canadian Society of Allergy and Clinical Immunology, Canadian Society of Otolaryngology-Head and Neck Surgery, Canadian Association of Emergency Physicians, and Family Physicians Airways Group of Canada). MAIN MESSAGE: Diagnosis of CRS is based on type and duration of symptoms and an objective finding of inflammation of the nasal mucosa or paranasal sinuses. Chronic rhinosinusitis is categorized based on presence or absence of nasal polyps, and this distinction leads to differences in treatment. Chronic rhinosinusitis with nasal polyps is treated with intranasal corticosteroids. Antibiotics are recommended when symptoms indicate infection (pain or purulence). For CRS without nasal polyps, intranasal corticosteroids and second-line antibiotics (ie, amoxicillin- clavulanic acid combinations or fluoroquinolones with enhanced Gram-positive activity) are recommended. Saline irrigation, oral steroids, and allergy testing might be appropriate. Failure of response should prompt consideration of alternative diagnoses and referral to an otolaryngologist. Patients undergoing endoscopic sinus surgery require postoperative treatment and follow-up. CONCLUSION: The Canadian guidelines provide diagnosis and treatment approaches based on the current understanding of the disease and available evidence. Additionally, the guidelines provide the expert opinion of a diverse group of practice and academic experts to help guide clinicians where evidence is sparse.
OBJECTIVE: To provide a clinical summary of the Canadian clinical practice guidelines for chronic rhinosinusitis (CRS) that includes recommendations relevant for family physicians. QUALITY OF EVIDENCE: Guideline authors performed a systematic literature search and drafted recommendations. Recommendations received both strength of evidence and strength of recommendation ratings. Input from external content experts was sought, as was endorsement from Canadian medical societies (Association of Medical Microbiology and Infectious Disease Canada, Canadian Society of Allergy and Clinical Immunology, Canadian Society of Otolaryngology-Head and Neck Surgery, Canadian Association of Emergency Physicians, and Family Physicians Airways Group of Canada). MAIN MESSAGE: Diagnosis of CRS is based on type and duration of symptoms and an objective finding of inflammation of the nasal mucosa or paranasal sinuses. Chronic rhinosinusitis is categorized based on presence or absence of nasal polyps, and this distinction leads to differences in treatment. Chronic rhinosinusitis with nasal polyps is treated with intranasal corticosteroids. Antibiotics are recommended when symptoms indicate infection (pain or purulence). For CRS without nasal polyps, intranasal corticosteroids and second-line antibiotics (ie, amoxicillin- clavulanic acid combinations or fluoroquinolones with enhanced Gram-positive activity) are recommended. Saline irrigation, oral steroids, and allergy testing might be appropriate. Failure of response should prompt consideration of alternative diagnoses and referral to an otolaryngologist. Patients undergoing endoscopic sinus surgery require postoperative treatment and follow-up. CONCLUSION: The Canadian guidelines provide diagnosis and treatment approaches based on the current understanding of the disease and available evidence. Additionally, the guidelines provide the expert opinion of a diverse group of practice and academic experts to help guide clinicians where evidence is sparse.
Authors: Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Allen D Adinoff; Claus Bachert; Larry Borish; Vernon M Chinchilli; Melvyn R Danzig; Berrylin J Ferguson; Wytske J Fokkens; Stephen G Jenkins; Valerie J Lund; Mahmood F Mafee; Robert M Naclerio; Ruby Pawankar; Jens U Ponikau; Mark S Schubert; Raymond G Slavin; Michael G Stewart; Alkis Togias; Ellen R Wald; Birgit Winther Journal: J Allergy Clin Immunol Date: 2006-11 Impact factor: 10.793
Authors: Vijay R Ramakrishnan; Todd T Kingdom; Jayakar V Nayak; Peter H Hwang; Richard R Orlandi Journal: Int Forum Allergy Rhinol Date: 2011-11-08 Impact factor: 3.858
Authors: Richard M Rosenfeld; David Andes; Neil Bhattacharyya; Dickson Cheung; Steven Eisenberg; Theodore G Ganiats; Andrea Gelzer; Daniel Hamilos; Richard C Haydon; Patricia A Hudgins; Stacie Jones; Helene J Krouse; Lawrence H Lee; Martin C Mahoney; Bradley F Marple; Col John P Mitchell; Robert Nathan; Richard N Shiffman; Timothy L Smith; David L Witsell Journal: Otolaryngol Head Neck Surg Date: 2007-09 Impact factor: 3.497
Authors: Pedro Benítez; Isam Alobid; Josep de Haro; Joan Berenguer; Manuel Bernal-Sprekelsen; Laura Pujols; Cesar Picado; Joaquim Mullol Journal: Laryngoscope Date: 2006-05 Impact factor: 3.325
Authors: Mahboobeh Mahdavinia; Mohamed Benhammuda; Christopher D Codispoti; Mary C Tobin; Philip S Losavio; Arpita Mehta; Jill S Jeffe; Sindhura Bandi; Anju T Peters; Whitney W Stevens; Alan Landay; Ali Keshavarzian; Robert P Schleimer; Pete S Batra Journal: J Allergy Clin Immunol Pract Date: 2016-01-20
Authors: Brett J Green; Donald H Beezhold; Zane Gallinger; Carly S Barron; Rochelle Melvin; Toni A Bledsoe; Michael L Kashon; Gordon L Sussman Journal: Allergy Asthma Clin Immunol Date: 2014-03-25 Impact factor: 3.406